BioLineRx is projected to report Q2 2026 consensus revenue of $0.50 million and a break-even EPS of $0.00, with its current $2.85 share price trading well below the $23.00 average analyst price target.
Investors are primarily focused on the commercial ramp of APHEXDA (motixafortide), specifically tracking whether royalties meet the $0.50 million Q2 2026 analyst consensus estimate.
Recent performance was bolstered by a 67% year-over-year revenue increase in Q1, reflecting the product's successful launch in stem cell mobilization for multiple myeloma. Additionally, shareholders are awaiting clinical updates regarding the Phase 1/2a trial of GLIX1 for glioblastoma treatment.